Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does DOXORUBICIN Cause Toxic epidermal necrolysis? 77 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 77 reports of Toxic epidermal necrolysis have been filed in association with DOXORUBICIN (Doxorubicin Hydrochloride). This represents 0.1% of all adverse event reports for DOXORUBICIN.

77
Reports of Toxic epidermal necrolysis with DOXORUBICIN
0.1%
of all DOXORUBICIN reports
34
Deaths
30
Hospitalizations

How Dangerous Is Toxic epidermal necrolysis From DOXORUBICIN?

Of the 77 reports, 34 (44.2%) resulted in death, 30 (39.0%) required hospitalization, and 24 (31.2%) were considered life-threatening.

Is Toxic epidermal necrolysis Listed in the Official Label?

Yes, Toxic epidermal necrolysis is listed as a known adverse reaction in the official FDA drug label for DOXORUBICIN.

What Other Side Effects Does DOXORUBICIN Cause?

Febrile neutropenia (8,844) Off label use (7,858) Disease progression (6,165) Neutropenia (5,891) Drug ineffective (4,598) Pyrexia (3,697) Thrombocytopenia (3,638) Anaemia (3,601) Product use in unapproved indication (3,502) Nausea (2,925)

What Other Drugs Cause Toxic epidermal necrolysis?

ACETAMINOPHEN (980) LAMOTRIGINE (941) ALLOPURINOL (858) IBUPROFEN (764) SULFAMETHOXAZOLE\TRIMETHOPRIM (592) CIPROFLOXACIN (576) FUROSEMIDE (521) VANCOMYCIN (515) PIPERACILLIN\TAZOBACTAM (490) PEMBROLIZUMAB (444)

Which DOXORUBICIN Alternatives Have Lower Toxic epidermal necrolysis Risk?

DOXORUBICIN vs DOXYCYCLINE DOXORUBICIN vs DOXYCYCLINE HYCLATE DOXORUBICIN vs DOXYCYCLINE\DOXYCYCLINE HYCLATE DOXORUBICIN vs DOXYLAMINE DOXORUBICIN vs DOXYLAMINE\PYRIDOXINE

Related Pages

DOXORUBICIN Full Profile All Toxic epidermal necrolysis Reports All Drugs Causing Toxic epidermal necrolysis DOXORUBICIN Demographics